The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
APOTEX-ZOLEDRONIC (Apotex Pty Ltd)
Product name
APOTEX-ZOLEDRONIC
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
177 (255 working days)
Active ingredients
Zoledronic acid monohydrate
Registration type
EOI
Indication
As an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.